Welcome to our dedicated page for Petvivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biomedical company’s disclosures is challenging—especially when Petvivo Holdings transforms complex human biomaterials into Spryng™ injections for pets. Revenue drivers hide in patent tables, while details about clinical milestones and distribution deals are scattered across multiple forms. If you have struggled to locate Petvivo Holdings insider trading Form 4 transactions or to decode a 300-page prospectus, you are not alone.
Stock Titan’s AI breaks down every document the moment it reaches EDGAR. Our platform delivers concise summaries, highlights crucial numbers, and links each insight back to the original page, so understanding Petvivo Holdings SEC documents with AI becomes straightforward. Whether you need a Petvivo Holdings quarterly earnings report 10-Q filing, an 8-K material events explained alert, or a proxy statement executive compensation table, you will find it here—complete with real-time updates and side-by-side comparisons.
Use the data to:
- Track Petvivo Holdings executive stock transactions Form 4 before product announcements.
- Compare segment revenue trends with our earnings report filing analysis.
- Review patent disclosures inside the annual report 10-K simplified.
From Petvivo Holdings Form 4 insider transactions real-time alerts to plain-language notes on R&D spending, our AI-powered summaries eliminate guesswork. Make faster, better-informed decisions—no more searching line-by-line through dense biomedical language.
PetVivo Holdings (PETV) reported Q2 FY2026 results. Revenue was $303,284 versus $200,720 a year ago, driven mainly by sales to Vedco after prior distributor agreements were terminated. Gross profit was $220,058. The company recorded a net loss of $3,007,809 for the quarter and $5,318,846 for the six months.
Cash was $767,914 and stockholders’ equity $4,182,972 at September 30, 2025. Total liabilities fell to $1,075,297 from $5,119,947, reflecting the conversion of $1,850,000 in convertible notes plus interest into 3,669,806 shares and the elimination of derivative liabilities. Operating cash outflow was $3,828,209 for the six months, partly offset by $4,361,829 of financing inflows, including receipt of the remaining $4,400,000 under the $5,000,000 Series B Preferred subscription (10% annual dividend payable in stock).
The company added two licensing assets: VetStem PRP ($2,000,000 fee) and an AI software license ($800,000 paid in stock). Shares outstanding were 33,580,630 as of November 14, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.
A.L. Sarroff Fund, LLC filed Amendment No. 10 to Schedule 13G reporting beneficial ownership of 8,846,288 shares of PetVivo Holdings, Inc. common stock, representing 31.7% of the class. The filer reports sole voting and sole dispositive power over the same 8,846,288 shares, with no shared power.
The filing states reliance on Rule 13d-1(c) and certifies the securities were not acquired to change or influence control. It also discloses 4,780,008 warrants with specified future exercisability dates that are not included in the Schedule 13G ownership per Rule 13d-3(d)(1). As context, the issuer had 27,903,361 shares outstanding as of August 14, 2025, and the filer notes its holdings were 26.5% as of June 30, 2025.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.
PetVivo Holdings (PETV) reported an insider transaction on Form 4. Chief Financial Officer Garry Lowenthal received 75,000 shares of restricted common stock on 10/23/2025 at a reported price of $1.27 per share. The grant was issued to a corporation owned by him as compensation for past performance. After this grant, he beneficially owns 667,967 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider transaction on a Form 4. CEO and Director John Lai acquired 75,000 shares of common stock on 10/23/2025 at $1.27 per share. The filing states the shares were a grant of restricted common stock to a corporation he owns, as compensation for past performance by converting a past accrued bonus into common stock.
After the transaction, Lai beneficially owned 2,095,710 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider equity award. Director Diane Levitan acquired 12,500 shares of restricted common stock at $1.28 on 10/10/2025. The award is part of an aggregate annual grant of 50,000 shares for Board service, vesting in four equal installments of 12,500 at the beginning of each quarter.
Following this transaction, Levitan beneficially owns 56,489 shares, held directly.
PetVivo Holdings (PETV) director reported multiple stock grants. On 10/01/2025, the director acquired 14,935 shares of restricted common stock at $1.19 as compensation for prior consulting services. On 10/10/2025, additional restricted stock grants were recorded: 12,500 shares at $1.28 for quarterly Board service vesting, 50,000 shares at $1.28 tied to a warrant exercise with a $25,000 payment to the company, and 100,000 shares at $1.28 tied to a warrant exercise with a $50,000 payment to the company. Following these transactions, beneficial ownership stood at 311,807 shares, held directly.
PetVivo Holdings (PETV) reported a Form 4 for director Robert Rudelius. On 10/10/2025, he acquired 12,500 shares of common stock at $1.28 as part of an annual 50,000 restricted-share board compensation grant that vests in four equal quarterly installments. Following the transaction, he beneficially owned 314,369 shares directly and 21,000 shares indirectly via a corporation.
PetVivo Holdings (PETV) reported a Form 4 showing Director Joseph Jasper acquired 12,500 restricted common shares at $1.28 on 10/10/2025. The transaction reflects the first quarterly vesting from an annual board compensation grant of 50,000 shares, vesting in four equal installments of 12,500 each.
Following the transaction, Jasper beneficially owned 100,159 shares directly, plus 2,000 shares indirectly held by his spouse.
FAQ
What is the current stock price of Petvivo Holdings (PETVW)?
